


GLP-1 MASTERCLASS

Your GLP-1 resource for type 2 diabetes

The GLP-1 Masterclass is a learning platform designed to keep healthcare professionals informed about developments in GLP-1 science and GLP-1 RA therapy for people living with type 2 diabetes mellitus (T2DM).

Section label

Learn more about GLP-1 and the role of GLP-1 RA therapy for type 2 diabetes



WHAT DOES GLP-1 NORMALLY DO?

What does GLP-1 normally do?

Glucagon-like peptide-1 (GLP-1) plays an important role in the body's response to high blood glucose and its actions are impacted by the progression of type 2 diabetes^{1,2}

[Check out Video](#)



WHAT IS GLP-1 RA THERAPY?

What is GLP-1 RA therapy?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an oral/injectable therapy that can be used to treat type 2 diabetes by mimicking the actions of natural GLP-1³

[Check out Video](#)



STRIKING UP A CONVERSATION?

Striking up a conversation ?

Don't miss the latest resources such as GLP-1 conversation starter

[Download your conversation starter](#)



FIND OUT ABOUT INDIA'S MOST RECENT GLP-1 RA

Find out about India's most recent GLP-1 RA

Be in the know about the most recent oral once weekly GLP-1 RA therapy in India and access a range of practical resources.

[Discover more](#)

Your Learning Modules



1. The science of GLP-1: Exploring Functions and Mechanisms



2. Evaluating multifactorial benefits of GLP-1 RA's



3. Strategic integration: Exploring GLP-1 RA's place in Therapy (guidelines)



4. The great comparison: Are all GLP-1 RA inhibitors equal?



5. Role of GLP-1 RA in Primary Care




6. Precision treatment: Patient Suitability for GLP-1 RA Treatment (Decisions – Patient Suitability)



7. Initiating GLP-1 RA Therapy: Best Practices (This topic can instead be on Striking up a Patient Conversation for GLP-1RA)



8. Synergistic approaches: Optimizing GLP-1 RA combination therapy



9. Clinical Curveballs: Handling Complex Cases with GLP-1 RA

References

1. Kjems LL et al. Diabetes 2003;52:380-86.
2. Andersen A et al. Nat Rev Endocrinol 2018;14:390-403.
3. Kim W & Egan JM. Pharmacol Rev 2008;60:470-512.

IN24RYB00199, Last Review date : 23/8/2024

LIST 1

- Contact us
- Novo Nordisk clinical trials
- Volunteer outreach programme
- Zero environmental impact
- Covid-19
- Report adverse events

LIST 2

- Contact us
- Novo Nordisk clinical trials
- Volunteer outreach programme
- Zero environmental impact
- Covid-19
- Report adverse events

LIST 3

- Contact us
- Novo Nordisk clinical trials
- Volunteer outreach programme
- Zero environmental impact
- Covid-19
- Report adverse events

